These included urokinase plasminogen activator (PLAU) a well characterized prognostic and predictive marker for breast cancer invasion, the cell adhesion metallopeptidase ADAM8, implicated in tumor-progressive degradation of ECM proteins, and a pro-inflammatory cytokine, TNFSF12. This evidence concerns the gene ADAM8 and breast cancer.